Elevated homocysteine level and folate deficiency associated with increased overall risk of carcinogenesis: Meta-analysis of 83 case-control studies involving 35,758 individuals

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Zhang, Donghong ^a   Wen, Xuemei ^b   Wu, Wei ^a   Guo, Ye ^a   Cui, Wei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ARTICLE; BLADDER CARCINOMA; CANCER CLASSIFICATION; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; DISEASE ASSOCIATION; ENZYME POLYMORPHISM; ETHNICITY; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; GASTROINTESTINAL CARCINOMA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; VITAMIN BLOOD LEVEL; ADULT; BLOOD; CARCINOMA; FEMALE; GASTROINTESTINAL NEOPLASMS; GENETICS; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; UROLOGIC NEOPLASMS;

ADULT; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; FOLIC ACID; FOLIC ACID DEFICIENCY; GASTROINTESTINAL NEOPLASMS; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; UROLOGIC NEOPLASMS;

EID: 84930656445     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123423     Document Type: Article

References (121)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Rock CL, Lampe JW, Patterson RE. Nutrition, genetics, and risks of cancer. Annu Rev Public Health. 2000; 21: 47-64. PMID: 10884945
3. Ferroni P, Palmirotta R, Martini F, Riondino S, Savonarola A, Spila A, et al. Determinants of homocysteine levels in colorectal and breast cancer patients. Anticancer Res. 2009; 29: 4131-4138. PMID: 19846961
4. Ulrich CM, Neuhouser M, Liu AY, Boynton A, Gregory JR, Shane B, et al. Mathematical modeling of folate metabolism: predicted effects of genetic polymorphisms on mechanisms and biomarkers relevant to carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1822-1831. doi: 10.1158/1055-9965.EPI-07-2937 PMID: 18628437
5. Bao Y, Michaud DS, Spiegelman D, Albanes D, Anderson KE, Bernstein L, et al. Folate intake and risk of pancreatic cancer: pooled analysis of prospective cohort studies. J Natl Cancer Inst. 2011; 103: 1840-1850. doi: 10.1093/jnci/djr431 PMID: 22034634
6. Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1632-1642. doi: 10.1158/1055-9965.EPI-10-0180 PMID: 20501771
7. Larsson SC, Giovannucci E, Wolk A. Folate and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. 2007; 99: 64-76. PMID: 17202114
8. Jang H, Mason JB, Choi SW. Genetic and epigenetic interactions between folate and aging in carcinogenesis. J Nutr. 2005; 135: 2967S-2971S. PMID: 16317156
9. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008; 134: 29-38. PMID: 18022173
10. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007; 297: 2351-2359. PMID: 17551129
11. Wu K, Platz EA, Willett WC, Fuchs CS, Selhub J, Rosner BA, et al. A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr. 2009; 90: 1623-1631. doi: 10.3945/ajcn.2009.28319 PMID: 19864409
12. Ebbing M, Bonaa KH, Nygard O, Arnesen E, Ueland PM, Nordrehaug JE, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA. 2009; 302: 2119-2126. doi: 10.1001/jama.2009.1622 PMID: 19920236
13. Zhang CX, Ho SC, Chen YM, Lin FY, Fu JH, Cheng SZ. Dietary folate, vitamin B6, vitamin B12 and methionine intake and the risk of breast cancer by oestrogen and progesterone receptor status. Br J Nutr. 2011; 106: 936-943. doi: 10.1017/S0007114511001140 PMID: 21736840
14. Johansson M, Relton C, Ueland PM, Vollset SE, Midttun O, Nygård O, et al. Serum B vitamin levels and risk of lung cancer. JAMA. 2010; 303: 2377-2385. doi: 10.1001/jama.2010.808 PMID: 20551408
15. Figueiredo JC, Levine AJ, Crott JW, Baurley J, Haile RW. Folate-genetics and colorectal neoplasia: what we know and need to know next. Mol Nutr Food Res. 2013; 57: 607-627. doi: 10.1002/mnfr.201200278 PMID: 23401104
16. Levine AJ, Figueiredo JC, Lee W, Poynter JN, Conti D, Duggan DJ, et al. Genetic variability in the MTHFR gene and colorectal cancer risk using the colorectal cancer family registry. Cancer Epidemiol Biomarkers Prev. 2010; 19: 89-100. doi: 10.1158/1055-9965.EPI-09-0727 PMID: 20056627
17. Zacho J, Yazdanyar S, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls. Int J Cancer. 2011; 128: 644-652. doi: 10.1002/ijc.25375 PMID: 20473868
18. Bai JL, Zheng MH, Xia X, Ter-Minassian M, Chen YP, Chen F. MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls. Eur J Cancer. 2009; 45: 1443-1449. doi: 10.1016/j.ejca.2009.01.020 PMID: 19223177
19. Zhang Y, Chen GQ, Ji Y, Huang B, Shen WS, Deng LC, et al. Quantitative assessment of the effect of MTHFR polymorphisms on the risk of lung carcinoma. Mol Biol Rep. 2012; 39: 6203-6211. doi: 10.1007/s11033-011-1439-1 PMID: 22215214
20. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, For GG. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ. 2004; 171:1369-73. PMID: 15557592
21. Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, et al. Serum folate and homocysteine levels in head and neck squamous cell carcinoma. Cancer. 2002; 94: 1006-1011. PMID: 11920469
22. Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, et al. Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia. Cancer. 2005; 103: 284-292. PMID: 15593092
23. Baltar VT, Xun WW, Johansson M, Ferrari P, Chuang SC, Relton C, et al. A structural equation modelling approach to explore the role of B vitamins and immune markers in lung cancer risk. Eur J Epidemiol. 2013; 28: 677-88. doi: 10.1007/s10654-013-9793-z PMID: 23532743
24. Bystrom P, Bjorkegren K, Larsson A, Johansson L, Berglund A. Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer. Ups J Med Sci. 2009; 114: 160-164. doi: 10.1080/03009730903027172 PMID: 19736606
25. Chandy S, Sadananda AM, Ramaswamy G, Ramachandra C, Krishnamoorthy L. Effect of Vitamin B (12) and Folate on Homocysteine levels in colorectal cancer. Indian J Clin Biochem. 2008; 23: 258-261. doi: 10.1007/s12291-008-0058-7 PMID: 23105766
26. Chung CJ, Pu YS, Su CT, Chen HW, Huang YK, Shiue HS, et al. Polymorphisms in one-carbon metabolism pathway genes, urinary arsenic profile, and urothelial carcinoma. Cancer Causes Control. 2010; 21: 1605-1613. doi: 10.1007/s10552-010-9589-3 PMID: 20532609
27. Eklof V, Van Guelpen B, Hultdin J, Johansson I, Hallmans G, Palmqvist R. The reduced folate carrier (RFC1) 80G > A and folate hydrolase 1 (FOLH1) 1561C > T polymorphisms and the risk of colorectal cancer: a nested case-referent study. Scand J Clin Lab Invest. 2008; 68: 393-401. doi: 10.1080/00365510701805431 PMID: 19172696
28. Eleftheriadou A, Chalastras T, Ferekidou E, Yiotakis I, Kyriou L, Tzagarakis M, et al. Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. Anticancer Res. 2006; 26: 2345-2348. PMID: 16821614
29. Falvo N, Ghiringhelli F, Berthier S, Bonnotte B, Lorcerie B. [Case-control study evaluating the incidence of hyperhomocysteinemia in cancer patients in an internal medicine department]. Rev Med Interne. 2007; 28: 520-525. PMID: 17537549
30. Gibson TM, Weinstein SJ, Mayne ST, Pfeiffer RM, Selhub J, Taylor PR, et al. A prospective study of one-carbon metabolism biomarkers and risk of renal cell carcinoma. Cancer Causes Control. 2010; 21: 1061-1069. doi: 10.1007/s10552-010-9534-5 PMID: 20383577
31. Gorgulu O, Selcuk T, Ozdemir S, Sayar C, Beyazit Y, Akbas Y. Evaluation of the roles of serum vitamin B(12), folate and homocysteine levels in laryngeal squamous cell carcinoma. J Int Med Res. 2010; 38: 2047-2052. PMID: 21227009
32. Hartman TJ, Woodson K, Stolzenberg-Solomon R, Virtamo J, Selhub J, Barrett MJ, et al. Association of the B-vitamins pyridoxal 5′-phosphate (B(6)), B(12), and folate with lung cancer risk in older men. Am J Epidemiol. 2001; 153: 688-694. PMID: 11282797
33. Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer. 2005; 113: 819-824. PMID: 15499634
34. Jatoi A, Daly BD, Kramer G, Mason JB. Folate status among patients with non-small cell lung cancer: a case-control study. J Surg Oncol. 2001; 77: 247-252. PMID: 11473373
35. Kedzierska M, Malinowska J, Glowacki R, Olas B, Bald E, Jeziorski A, et al. The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients. Mol Cell Biochem. 2011; 355: 193-199. doi: 10.1007/s11010-011-0854-x PMID: 21533764
36. Le Marchand L, White KK, Nomura AM, Wilkens LR, Selhub JS, Tiirikainen M, et al. Plasma levels of B vitamins and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2195-2201. doi: 10.1158/1055-9965.EPI-09-0141 PMID: 19661077
37. Lee JE, Li H, Giovannucci E, Lee IM, Selhub J, Stampfer M, et al. Prospective study of plasma vitamin B6 and risk of colorectal cancer in men. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1197-1202. doi: 10.1158/1055-9965.EPI-08-1001 PMID: 19336555
38. Mohammad NS, Yedluri R, Addepalli P, Gottumukkala SR, Digumarti RR, Kutala VK. Aberrations in one-carbon metabolism induce oxidative DNA damage in sporadic breast cancer. Mol Cell Biochem. 2011; 349: 159-167. doi: 10.1007/s11010-010-0670-8 PMID: 21113649
39. Nacci A, Dallan I, Bruschini L, Traino AC, Panicucci E, Bruschini P, et al. Plasma homocysteine, folate, and vitamin B12 levels in patients with laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2008; 134: 1328-1333. doi: 10.1001/archotol.134.12.1328 PMID: 19075131
40. Ozkan Y, Yardim-Akaydin S, Firat H, Caliskan-Can E, Ardic S, Sim?ek B. Usefulness of homocysteine as a cancer marker: total thiol compounds and folate levels in untreated lung cancer patients. Anticancer Res. 2007; 27: 1185-1189. PMID: 17465261
41. Pathak S, Bhatla N, Singh N. Cervical cancer pathogenesis is associated with one-carbon metabolism. Mol Cell Biochem. 2012; 369: 1-7. doi: 10.1007/s11010-012-1362-3 PMID: 22729741
42. Pufulete M, Al-Ghnaniem R, Leather AJ, Appleby P, Gout S, Terry C, et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology. 2003; 124: 1240-1248. PMID: 12730865
43. Safarinejad MR, Shafiei N, Safarinejad S. Methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C and G1793A polymorphisms: association with risk for clear cell renal cell carcinoma and tumour behaviour in men. Clin Oncol (R Coll Radiol). 2012; 24: 269-281. doi: 10.1016/j.clon.2011.03.005 PMID: 21489764
44. Safarinejad MR, Shafiei N, Safarinejad S. Genetic susceptibility of methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C, and G1793A polymorphisms with risk for bladder transitional cell carcinoma in men. Med Oncol. 2011; 28 Suppl 1: S398-S412. doi: 10.1007/s12032-010-9723-9 PMID: 21046286
45. Safarinejad MR, Shafiei N, Safarinejad S. Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: a case-control study. Prostate. 2010; 70: 1645-1657. doi: 10.1002/pros.21200 PMID: 20564317
46. Schernhammer E, Wolpin B, Rifai N, Cochrane B, Manson JA, Ma J, et al. Plasma folate, vitamin B6, vitamin B12, and homocysteine and pancreatic cancer risk in four large cohorts. Cancer Res. 2007; 67: 5553-5560. PMID: 17545639
47. Schroecksnadel K, Frick B, Fiegl M, Winkler C, Denz HA, Fuchs D, et al. Hyperhomocysteinemia and immune activation in patients with cancer. Clin Chem Lab Med. 2007; 45: 47-53. PMID: 17243914
48. Weinstein SJ, Albanes D, Selhub J, Graubard B, Lim U, Taylor PR, et al. One-carbon metabolism biomarkers and risk of colon and rectal cancers. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3233-3240. doi: 10.1158/1055-9965.EPI-08-0459 PMID: 18990766
49. Zhang SM, Willett WC, Selhub J, Hunter DJ, Giovannucci EL, Holmes MD, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst. 2003; 95: 373-380. PMID: 12618502
50. de Vogel S, Meyer K, Fredriksen A, Ulvik A, Ueland PM, Nygård O, et al. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk - a Norwegian population-based nested case-control study of 3000 cases and 3000 controls within the JANUS cohort. Int J Epidemiol. 2013; 42: 201-210. doi: 10.1093/ije/dys199 PMID: 23508410
51. Wei K, Huang Y. Relationship between plasma homocysteine, folate and vitaminB12 levels and non-small cell lung cancer. Int J Lab Med. 2012; 33: 699-701.
52. Yan LD, Li P-ping Z. Analysis of clinical significance for the detection of serum homocysteine for digestive system cancer patients. Modern preventive Medicine. 2012; 39: 1754-1755.
53. Fu ZB, Shi ZN, Cheng LH, Rong NL, Di X. The clinical significance of Serumhomocystein inprimary hepatic carcinoma. Modern Oncology. 2010; 18: 767-768.
54. He HM, Zhu F, Shi GL, Huangpu YM. Determination of pre and post-operative contents of plasma homocysteine and serum folic acid and vitamine B12 in patients with esophageal cancer and its clinical significance. MEDICAL JOURNAL OF THE CHINESE PEOPLE'S ARMED POLICE FORCES. 2010; 21: 481-482, 485.
55. Guo AZ, Cai QC, Chen Y, Zhu W, Li SD, Li ZS. Relationship of folic acid, homcysteine with pancreatic cancer: a case-control study. Academic Journal of Second Military Medical University. 2009; 30: 420-423.
56. Yang CX, Bian BX, Hu N. Clinical Significance of Determination of Changes of Plasma of Hcy and Serum Folic Acid, VitminB12 Levels After Operation in Patients with Primary Hepatic Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2008; 21: 116-117.
57. Zhu PM. Clinical Significance of Determination of Changes of Serum Homocysteine Levels in Patients with Maligant Tumors of Digestive System. JOURNAL OF RADIOIMMUNOLOGY. 2007; 20: 587-589.
58. Qiao R, Zhang J, Wang ZH, Liang GC, Wu YH. Initial Investigation of the Level of Total Plasma Homocysteine in 7 Kinds of Tumor. J Mod Lab Med. 2006; 21: 7-10.
59. Xu J, Xu HM, Wang YM, Huang PZ, Li ZM. Relationship between plasma homocysteine and serum folate in patients with gynecology tumor. CHINA ONCOLOGY. 2000; 10: 78-80.
60. Battistelli S, Vittoria A, Stefanoni M, Bing C, Roviello F. Total plasma homocysteine and methylenetetrahydrofolate reductase C677T polymorphism in patients with colorectal carcinoma. World J Gastroenterol. 2006; 12: 6128-6132. PMID: 17036383
61. Ko KH, Kim NK, Yim DJ, Hong SP, Park PW, Rim KS, et al. Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population. Anticancer Res. 2006; 26: 4229-4233. PMID: 17201138
62. Kohaar I, Kumar J, Thakur N, Hussain S, Niyaz MK, Das BC, et al. Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population. Biomarkers. 2010; 15: 61-68. doi: 10.3109/13547500903295881 PMID: 19793004
63. Komlosi V, Hitre E, Pap E, Adleff V, Reti A, Szekely E, et al. SHMT1 1420 and MTHFR 677 variants are associated with rectal but not colon cancer. BMC Cancer. 2010; 10: 525. doi: 10.1186/1471-2407-10-525 PMID: 20920350
64. Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S, et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res. 2004; 10: 1312-1317. PMID: 14977830
65. Williams EA, Welfare M, Spiers A, Hill MH, Bal W, Gibney ER, et al. Systemic folate status, rectal mucosal folate concentration and dietary intake in patients at differential risk of bowel cancer (The FAB2 Study). Eur J Nutr. 2013; 52: 1801-1810. doi: 10.1007/s00394-012-0483-5 PMID: 23271614
66. Yin G, Ming H, Zheng X, Xuan Y, Liang J, Jin X. Methylenetetrahydrofolate reductase C677T gene polymorphism and colorectal cancer risk: A case-control study. Oncol Lett. 2012; 4: 365-369. PMID: 22844384
67. Eroglu A, Egin Y, Akar N. The effects of tamoxifen on homocysteine levels in breast cancer patients. CENTRAL EUROPEAN JOURNAL OF MEDICINE. 2009; 4: 450-453.
68. Gatt A, Makris A, Cladd H, Burcombe RJ, Smith JM, Cooper P, et al. Hyperhomocysteinemia in women with advanced breast cancer. Int J Lab Hematol. 2007; 29: 421-425. PMID: 17988296
69. Hwang NC, Kim YH, Shim SG, Son HJ, Rhee PL, Kim JJ, et al. [Is serum homocysteine level elevated in colorectal tumor?]. Korean J Gastroenterol. 2005; 45: 97-102. PMID: 15725713
70. Kedzierska M, Glowacki R, Czernek U, Szydlowska-Pazera K, Potemski P, Piekarski J, et al. Changes in plasma thiol levels induced by different phases of treatment in breast cancer; the role of commercial extract from black chokeberry. Mol Cell Biochem. 2013; 372: 47-55. doi: 10.1007/s11010-012-1444-2 PMID: 22949034
71. Lin J, Lee IM, Song Y, Cook NR, Selhub J, Manson JE, et al. Plasma homocysteine and cysteine and risk of breast cancer in women. Cancer Res. 2010; 70: 2397-2405. doi: 10.1158/0008-5472.CAN-09-3648 PMID: 20197471
72. Miller JW, Beresford SA, Neuhouser ML, Cheng TY, Song X, Brown EC, et al. Homocysteine, cysteine, and risk of incident colorectal cancer in the Women's Health Initiative observational cohort. Am J Clin Nutr. 2013; 97: 827-834. doi: 10.3945/ajcn.112.049932 PMID: 23426034
73. Samonakis DN, Koutroubakis IE, Sfiridaki A, Malliaraki N, Antoniou P, Romanos J, et al. Hypercoagulable states in patients with hepatocellular carcinoma. Dig Dis Sci. 2004; 49: 854-858. PMID: 15259509
74. Zhang CY. Clinical Significance of Measurement of Changes of Serum CA125, Hcy and HE4 Levels After Operation in Patients with Ovarian Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2012; 25: 406-408.
75. Fang YC, Jiang HP, Zeng RM, Dong Y, Yuan ML. Detection of plasma homocysteine in patientswith liver cirrhosis and liver cancer and its clinical value. Chinese Journal of Health Laboratory Technology. 2009; 19: 2875-2876.
76. Ding HB, Nan YG, Jiang CY. Clinical Assessment of Determination of Changes of Serum CA72-4, Hcy and CysC Levels Both Before and After Operation in Patients with Gastric Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2011; 24: 639-641.
77. He BH, Chen GH, Pan YP, Shao ZF. Clinical Significance of Determination of Changes on Serum Hcy, CA-72-4 and VEGF Levels Both Before and After Operation in Patients with Esophageal Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2012; 25: 500-502.
78. He BH, Chen GH, Pan YP. Clinical Significance of Determination of Changes of Serum Hcy, IGF-II and TSGF Levels After Operation in Patients with Esophageal Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2010; 23: 491-492.
79. Li HL, Li HM, Li B. The detection and analysis of serum homocysteine and cystatin C level in patients with malignancy. Chinese Journal of Primary Medicine and Pharmacy. 2012; 19: 3208-3209.
80. Tai YH, Wang F, Tang ZQ. Clinical significance of measurement of serum vascular endothelial growth factor(VEGF) and plasma homocysteine(HCY) levels before and after operation in patients with gastric cancer. JOURNAL OF HUAIHAI MEDICINE. 2009; 27: 195-196.
81. Huang YQ, Liu B, Zahng YH. Clinical value of combination of AFU, GGT, ALP and Hcy for diagnosis in patients with primary hepatocarcinoma. China Journal of Modern Medicine. 2011; 21: 1359-1361.
82. Zhang SH, Liang ZJ, Huang FW. The value of serum homocysteine in primary hepatocarcinoma. Modern Oncology. 2012; 20: 2580-2581.
83. Wang LN, Ke Q, Chen WS, Zhou Y, Tan YF, Wang JM, et al. Study on the association between total plasma homocysteine levles, dietary habits and the risk of gastric cancer. Chin J Epidemiol. 2007; 28: 528-531.
84. Zhou LH, Deng DY, Liu CL, Xue YS, Zhi GH, Zhao DY, et al. Analysis of relationship between serum homocysteine level and breast tumor. LABORATORY MEDICINE AND CLINIC. 2011; 08: 687-688.
85. Wang LY, Ma L, Su JR. Initial investigation of serum homocysteine as cancer biomarker. International Journal of Surgery. 2012; 39: 752-755.
86. Lan LD, Huang RY, He B. The value of combined of AFP, AFU and Hcy for diagnosis in patients with primary hepatocarcinoma. CHINESE AND FOREIGN MEDICAL RESEARCH. 2011; 9: 53-54.
87. Ma JG, Yao JP, Mao CH, Zhao XG. Clinical Significance of Measurement of Changes of Plasma Leptin and Serum Hcy, NPY Levels Before and After Chemotherapy in Patients with Lung Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2011; 24: 502-504.
88. Qiao R, Zhang J, Hu XQ, Liang GC, Wu YH. Level of Total Plasma Homocysteine in Colorectal Cancer and Liver Cancer Patients and its Influence in Proliferation. Chin J Misdiagn. 2009; 9: 2773-2775.
89. Wang R, Zhou J, Sun J. Clinical significance of combined detection to serum levels of CA153, HCY and VEGF before and after operation to breast cancer patients. CHINESE JOURNAL OF SURGICAL ONCOLOGY. 2011; 03: 341-343.
90. Wang SG, Feng LF, Wang YM, Liu GR, Li D, Zhang L. Correlation studies of homocysteine and malignant tumor. CHINA MEDICAL HERALD. 2011; 8: 157-158.
91. Liu W, Ma YY, Wu YS, Sun XW, Shen BZ. The Relationship between Serum Homocysteine and Malignant Tumors. Journal of cancer prevention research. 2006; 33: 191-193.
92. Du X, Li SK, Huang SX. Expression and significance on homocysteine in primary hepatic carcinoma. Modern Preventive Medicine. 2012; 39: 3379-3380.
93. Chen XC. Clinical Significance of Combined Detection of Serum Hcy, HE4 and SA Levels in Patients with Ovarian Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2012; 25: 187-188.
94. Wang XY. Clinical Significance of Determination the Changes of Serum Hcy,CEA and VEGF Levels After Operation in Patients with Esophageal Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2011; 24: 622-624.
95. Zhang XQ, Ni SS. Roles of VWT, GMP-140, TPP Hcy in diagnosing prethrombosis state of lung cancer. Journal of clinical pulmonary. 2010; 15: 1433-1435.
96. Zhu WX. Diagnostic Values of Combined Measurement of Serum CA19-9, Hcy, CA50 and Sialic Acid in Patients with Pancreatic Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2011; 24: 132-133.
97. Ji YJ, Wang X, Liu ZH. Clinical Significance of Determination of Changes of Serum Hcy, IGF-II and TSGF Levels After Chemotherapy in Patients with Lung Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2008; 12: 512-514.
98. Deng YL, Zheng LP. Analysis of the relationship between serum homocysteine level and breast tumor. Modern Preventive Medicine. 2012; 34:87-89.
99. Zhang YL, Shi HM, Fan NF, Feng YJ, Kang Y. Analysis of serum homocysteine levels in patients with colorectal cancer. Cancer Research and Clinic. 2012; 24: 550-552.
100. Ge YB, Shi SD. Clinical Significance of Changes of SerumCA50, CA242 and Hcy Levels in postoperative Patients with Colorectal Cancer. JOURNAL OF RADIOIMMUNOLOGY. 2012; 25: 12-14. doi: 10.1186/1687-9856-2012-25 PMID: 22992277
101. Liu YL, Gao YH, Tian YP, Wen XY. Expression of homocysteine in serum of malignant tumor patients. J Chinese PLA Postgrad Med Sch. 2011; 32: 1085-1086.
102. Lamonica-Garcia VC, Marin FA, Lerco MM, Moreto F, Henry MA, Burini RC. [Plasma taurine levels in patients with esophagus cancer]. Arq Gastroenterol. 2008; 45: 199-203. PMID: 18852946
103. Duthie SJ. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis. 2011; 34: 101-109. doi: 10.1007/s10545-010-9128-0 PMID: 20544289
104. Wang TC, Song YS, Wang H, Zhang J, Yu SF, Gu YE, et al. Oxidative DNA damage and global DNA hypomethylation are related to folate deficiency in chromate manufacturing workers. J Hazard Mater. 2012; 213-214: 440-446.
105. Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, Johnson KA, Johnson C, Buys SS, et al. Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr. 2006; 83: 895-904. PMID: 16600944
106. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007); 297: 2351-2359. PMID: 17551129
107. Ebbing M, Bonaa KH, Nygard O, Arnesen E, Ueland PM, Nordrehaug JE, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA. 2009; 302: 2119-2126. doi: 10.1001/jama.2009.1622 PMID: 19920236
108. Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst. 2009; 101: 432-435. doi: 10.1093/jnci/djp019 PMID: 19276452
109. Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1325-1329. PMID: 17626997
110. Song J, Medline A, Mason JB, Gallinger S, Kim YI. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res. 2000; 60: 5434-5440. PMID: 11034085
111. Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res. 2007; 51: 267-292. PMID: 17295418
112. Larsson SC, Giovannucci E, Wolk A. Folate and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. 2007; 99: 64-76. PMID: 17202114
113. Park SY, Kolonel LN, Lim U, White KK, Henderson BE, Wilkens LR. Alcohol consumption and breast cancer risk among women from five ethnic groups with light to moderate intakes: The Multiethnic Cohort Study. Int J Cancer. 2013; 134: 1504-1510. doi: 10.1002/ijc.28476 PMID: 24037751
114. Voevodina O, Billich C, Arand B, Nagel G. Association of Mediterranean diet, dietary supplements and alcohol consumption with breast density among women in South Germany: a cross-sectional study. BMC Public Health. 2013; 13: 203. doi: 10.1186/1471-2458-13-203 PMID: 23497280
115. Ubbink JB, Delport R, Vermaak WJ. Plasma homocysteine concentrations in a population with a low coronary heart disease prevalence. J Nutr. 1996; 126:1254S-57S. PMID: 8642466
116. Must A, Jacques PF, Rogers G, Rosenberg IH, Selhub J. Serum total homocysteine concentrations in children and adolescents: results from the third National Health and Nutrition Examination Survey (NHANES III). J Nutr. 2003; 133:2643-49. PMID: 12888652
117. Ubbink JB, Vermaak WJ, Delport R, van der Merwe A, Becker PJ, et al. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr. 1995; 62:802-8. PMID: 7572713
118. Ragasudha PN, Thulaseedharan JV, Wesley R, Jayaprakash PG, Lalitha P, Pillai MR. A case-control nutrigenomic study on the synergistic activity of folate and vitamin B12 in cervical cancer progression. Nutr Cancer. 2012; 64: 550-558. doi: 10.1080/01635581.2012.675618 PMID: 22519865
119. Ishihara J, Otani T, Inoue M, Iwasaki M, Sasazuki S, Tsugane S. Low intake of vitamin B-6 is associated with increased risk of colorectal cancer in Japanese men. J Nutr. 2007; 137: 1808-1814. PMID: 17585035
120. Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 1999; 8: 513-518. PMID: 10385141
121. Hegele RA, Tully C, Young TK, Connelly PW. V677 mutation of methylenetetrahydrofolate reductases and cardiovascular disease in Canadian Inuit. Lancet. 1997; 349:1221-2. PMID: 9130949